- Oxford Biomedica
- 11 June 2025 11:22:05
Source: Sharecast
The London-listed cell and gene therapy-focused CDMO noted in a brief update ahead of its annual general meeting that it had seen strong operational and commercial progress year-to-date, with viral vector manufacturing services being delivered to a broad and diversified client base.
It reiterated the outlook published in its preliminary results for the year ended 31 December, maintaining confidence in its strategic direction and delivery targets for the current year.
“We have delivered strong operational performance so far in the first half of the year, reflecting disciplined execution across our global sites and sustained commercial momentum,” said chief executive officer Dr Frank Mathias.
“The company reiterates its financial guidance today and remains focused on supporting clients across all stages of development.
“OXB remains confident in its near and medium-term targets as set out earlier this year.”
At 1056 BST, shares in Oxford Biomedica were up 3.3% at 344.5p.
Reporting by Josh White for Sharecast.com.